RecruitingNot Applicable

Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

South Korea160 participantsStarted 2024-01

Plain-language summary

This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults age 19 and above ( no age limit for elderly ) * Patients with cardiogenic shock requiring intensive care monitoring in ICU * Patients eligible for oral medication administration * Patients who have provided research participation consent through a written informed consent form Exclusion Criteria: * Unwilling or unable to obtain informed consent by the participant or substitute decision maker * Patients with mechanical circulatory support at the time of screening * Patients with acute coronary syndrome * Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery * Known hypersensitivity to beta-blockers * Patients with a history of bronchospasm or asthma * Patients with bradycardia or second or third-degree atrioventricular block * Patients with sick sinus syndrome, including sinoatrial block * Patients with untreated pheochromocytoma * Patients currently undergoing de-sensitization therapy * Patients who are currently pregnant, postpartum period within 30 days or breast-feeding

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

30-day all-cause mortality

Timeframe: From date of randomization until the date of death from any cause, assessed up to 30 days

Trial details

NCT IDNCT06078436

SponsorMin-Seok Kim

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-09

Contact for this trial

Min-Seok Kim, PhD

82-2-3010-3948 msk@amc.seoul.kr

View on ClinicalTrials.gov More Heart Failure With Reduced Ejection Fraction trials